Trial Profile
A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to Nilotinib in Patients With CML-CP Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Asciminib (Primary) ; Imatinib (Primary) ; Nilotinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms ASC4MORE
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 27 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 01 Jan 2024 Planned End Date changed from 5 Nov 2027 to 4 Apr 2025.
- 12 Dec 2023 Results (cutoff: 6 Mar 2023),Asciminib Add-on to Imatinib,presented at the 65th American Society of Hematology Annual Meeting and Exposition